PhRMA Continues Critique of ICER Drug Pricing Studies

The Pharmaceutical Research and manufacturers of America (PhRMA) have repeatedly spoken out against the cost-effectiveness studies published by the Institute for Clinical and Economic Review (ICER) and has recently publicized its own four pointed list of recommendations to ICER. Read more here. (Source: Joe Cantlupe, BioPharma DIVE, 9/29/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
Real World Evidence (RWE) Solutions Market by Component,… 02/05/2020
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
Research Operations for Secondary Use of Clinical Sites’ EMR 11/21/2019